Trials / Terminated
TerminatedNCT04730505
A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM
A Multi-center, Randomized, Pilot Trial to Evaluate the My Hematology Oncology Patient Experience (MYHOPE™) for Multiple Myeloma (MM) Digital Care Network in Patients With MM
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
NDS-MM-004 is a multi-center, randomized, pilot trial to evaluate the MyHOPE for multiple myeloma (MM) Platform in patients with MM. The MyHOPE for MM Platform is a validated investigational device manufactured by Amalgam Rx, Inc. and designed to provide patients with a comprehensive set of tools and resources to support the patient throughout their overall experience with MM.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | MyHOPE™ for Multiple Myeloma | The MyHOPE for MM Platform is designed to provide patients with tools and resources to support them in their overall experience with MM. Patients can share their data through a PDF or by showing their device to their care team at clinic visits. |
| DEVICE | MyHope HCP Portal | Is designed to provide HCPs with the ability to view patient data and symptom notifications (Cohort 1 only) to provide support between clinic visits and to facilitate dialogue during clinic visits. |
Timeline
- Start date
- 2021-02-04
- Primary completion
- 2021-06-21
- Completion
- 2021-06-21
- First posted
- 2021-01-29
- Last updated
- 2021-08-09
Locations
34 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04730505. Inclusion in this directory is not an endorsement.